Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Free Report) - HC Wainwright dropped their Q4 2025 earnings per share (EPS) estimates for Armata Pharmaceuticals in a note issued to investors on Monday, May 19th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of ($0.86) per share for the quarter, down from their prior forecast of ($0.67). HC Wainwright has a "Buy" rating and a $9.00 price objective on the stock. The consensus estimate for Armata Pharmaceuticals' current full-year earnings is ($0.95) per share.
Armata Pharmaceuticals Price Performance
Shares of ARMP stock opened at $2.25 on Wednesday. Armata Pharmaceuticals has a twelve month low of $0.90 and a twelve month high of $3.42. The stock's fifty day moving average price is $1.45. The company has a market cap of $81.41 million, a price-to-earnings ratio of -1.37 and a beta of 0.87.
About Armata Pharmaceuticals
(
Get Free Report)
Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Armata Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Armata Pharmaceuticals wasn't on the list.
While Armata Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
